C4 Therapeutics(CCCC) - 2024 Q1 - Quarterly Results

Exhibit 99.1 C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights Successfully Delivered First Development Candidate to Biogen; $8 Million Payment Earned Established a Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Focused on Two Critical Oncogenic Proteins Progressed Phase 1 Dose Escalation Trials for Cemsidomide (CFT7455) and CFT1946; Data from Both Trials Expected in 2H 2024 Cash, Cash Equivalents and Marketable Securities Total $299 ...